Obesity

Researchers have successfully tweaked a specialized compound from brown seaweed to unlock its powerful anti-obesity potential. Instead of appetite suppression and fat burning, this molecule reshapes the gut microbiome to fight weight gain naturally.

Obesity before pregnancy, not just during, may shape a child’s brain and raise the risk of autism, a new study has found. Epigenetic changes in eggs triggered gene shifts linked to autism-like behaviors, revealing a critical window for prevention.

Tiny "hidden" proteins lurking in DNA once dismissed as junk may hold the key to the next generation of obesity drugs, according to a new study that has uncovered dozens of new fat-regulating molecules using cutting-edge gene-editing technology.

A huge international study has identified a weekly disturbance in one of the world’s most common sleep disorders, obstructive sleep apnea. Introducing “social apnea” – when the severity of the disorder jumps by nearly 20% on these specific nights.

It looks like we'll see oral GLP-1 drugs on the market by 2026, with Eli Lilly reporting impressive results from a large, robust 72-week trial that saw obese patients lose an average of 27.3 lb, or 12.4% of their body weight, with a once-daily pill.

Byproducts from gut bacteria breaking down tryptophan, a dietary amino acid, can restore hormone-secreting gut cells reduced by obesity, a new study found. It opens the door to a natural, side-effect-free alternative to GLP-1 drugs like Ozempic.

While obesity significantly increases the risk of many cancers, scientists have now uncovered that there are specific dietary fat drivers that impede the body's ability to fight tumors. This landmark reveals that not all fats are created equal.

In a landmark 14-year study, researchers found that artificially sweetened drinks raise the risk of developing type 2 diabetes by more than a third, higher than those with sugar. It challenges the perception that diet drinks are healthier options.

The US Food and Drug Administration has instructed all GLP-1 drug-makers to update warning labels to include the risk of serious kidney injury that can result from dehydration. This comes after cases of acute kidney injury have required hemodialysis.

The first human-tested weight-loss drug that burns calories through creatine-based heat generation, without reducing appetite, has successfully completed its Phase I trial. In the trial, participants lost an average of 3% fat mass in two weeks.

For decades now, obesity has been defined by a number on a scale or where you land on the body mass index measure. But a groundbreaking study has found that it’s far more complex, finding 11 distinct biological types, each with their own health risks.

What if you could inject a drug into a "problem area" – like the abdomen – and have it safely and rapidly kill off fat cells? We could be within 12 months of this reality, as the world's first safe, targeted fat-loss jab enters Phase 3 trials.